Recent advances in cancer immunotherapy with anti-programmed cell death (PD1) and anti-programmed cell death ligand 1 (PD-L1) inhibitors have shown significant survival benefits in advanced non-small cell lung carcinoma (NSCLC), leading to impressive outcomes [1,2,3]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.